|
Athira Pharma Inc (NASDAQ: ATHA) |
|
Athira Pharma Inc
ATHA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Athira Pharma Inc 's sales fell
in IV. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.45 %
Athira Pharma Inc net loss decreased from $-33 millions, to $-9 millions in IV. Quarter 2024,
• More on ATHA's Growth
|
|
Athira Pharma Inc realized a net loss in trailing twelve months.
Athira Pharma Inc realized cash reduction of $ -1.61 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
• More on ATHA's Valuation
|
|
|
|
|
Athira Pharma Inc realized net loss in trailing twelve months.
Athira Pharma Inc realized cash outflow of $ -1.61per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
Athira Pharma Inc Price to Book Ratio is at 0.2 lower than Industry Avg. of 17782.13. and higher than S&P 500 Avg. of 0.01
• More on ATHA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com